ibogaine ibogaine ibogaine is a naturally occurring psychoactive substance found in plants in the family apocynaceae such as tabernanthe iboga, voacanga africana, and tabernaemontana undulata. it is a psychedelic with dissociative properties. ibogaineclinical dataother names12-methoxyibogamineroutes ofadministrationoralatc codenonelegal statuslegal status au: s4 (prescription only) ca: prescription only nz: prescription only uk: under psychoactive substances act us: schedule i un: unscheduled identifiers iupac name (1r,15r,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclononadeca-2(10),4(9),5,7-tetraene cas number83-74-9 ypubchem cid197060chemspider170667 yunii3s814i130uchebichebi:5852chemblchembl1215855 ycomptox dashboard (epa)dtxsid20894069 echa infocard100.001.363 chemical and physical dataformulac20h26n2omolar mass310.441 g·mol−13d model (jsmol)interactive imagemelting point152 to 153 °c (306 to 307 °f) smiles cc1c2c3c4c5ccc(oc)cc5c4cc(c2)13 inchi inchi=1s/c20h26n2o/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21h,3,6-9,11h2,1-2h3/t12-,13+,17+,20+/m1/s1 ykey:hsibgvumfosjpd-cfdpkngzsa-n y (verify) preliminary research indicates that it may help counter drug addiction. however, its use has been associated with serious side effects and death. between the years 1990 and 2008, a total of 19 fatalities temporally associated with the ingestion of ibogaine were reported, from which six subjects died of acute heart failure or cardiopulmonary arrest. the total number of subjects who have used it without major side effects during this period remains unknown. it is used as an alternative medicine treatment for drug addiction in some countries. its prohibition in other countries has slowed scientific research. ibogaine is also used to facilitate psychological introspection and spiritual exploration. various derivatives of ibogaine designed to lack psychedelic properties (such as 18-mc) are under clinical trials which have shown them to be neither psychedelic nor psychoactive and to have acceptable safety profiles in humans. the psychoactivity of the root bark of the iboga tree (tabernanthe iboga), from which ibogaine is extracted, was first discovered by the pygmy tribes of central africa, who passed the knowledge to the bwiti tribe of gabon. french explorers in turn learned of it from the bwiti tribe and brought ibogaine back to europe in 1899–1900, where it was subsequently marketed in france as a stimulant under the trade name lambarène. ibogaine-containing preparations are used for medicinal and ritual purposes within the african spiritual traditions of the bwiti, who claim to have learned it from the pygmy peoples. although ibogaine's anti-addictive properties were first widely promoted in 1962 by howard lotsof, its western medical use predates that by at least a century. additionally, the u.s. central intelligence agency (cia) studied the effects of ibogaine in the 1950s. ibogaine is an indole alkaloid that is obtained either by extraction from the iboga plant or by semi-synthesis from the precursor compound voacangine, another plant alkaloid. the total synthesis of ibogaine was described in 1956. structural elucidation by x-ray crystallography was completed in 1960. psychoactive effects ibogaine is derived from the root of the tabernanthe iboga, a plant known to exhibit psychedelic effects in its users. the experience of ibogaine occurs in two phases, termed the visionary phase and the introspection phase. the visionary phase has been described as oneirogenic, referring to the dreamlike nature of its psychedelic effects, and lasts for 4 to 6 hours. the second phase, the introspection phase, is responsible for the psychotherapeutic effects. it can allow people to conquer their fears and negative emotions. ibogaine catalyzes an altered state of consciousness reminiscent of dreaming while fully conscious and aware so that memories, life experiences, and issues of trauma can be processed. uses ibogaine-containing shredded bark of tabernanthe iboga for consumption medical